Betta Pharmaceuticals Co., Ltd. (300558) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 12.38% and Operating profit at 4.42% over the last 5 years

Negative results in Jun 25

With ROE of 6.92%, it has a very expensive valuation with a 4.95 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CNY 27,699 Million (Large Cap)

P/E

72.00

Industry P/E

Dividend Yield

0.30%

Debt Equity

0.32

Return on Equity

6.92%

Price to Book

4.95

Revenue and Profits:

Net Sales:

805 Million

(Quarterly Results - Jun 2025)

Net Profit:

35 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-36.79%

6 Months

-22.52%

1 Year

-17.49%

2 Years

-15.98%

3 Years

-5.43%

4 Years

-41.08%

5 Years

-51.24%

Betta Pharmaceuticals Co., Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Betta Pharmaceuticals Hits Day Low of CNY 56.56 Amid Price Pressure

Betta Pharmaceuticals Co., Ltd. faced notable market activity on October 15, 2025, with a significant decline in stock value. Despite recent short-term challenges, the company has shown strong annual performance, outperforming the China Shanghai Composite. Financial metrics reveal a market capitalization of CNY 27,699 million and a price-to-earnings ratio of 72.00.

Betta Pharmaceuticals Hits Day Low of CNY 56.08 Amid Price Pressure

Betta Pharmaceuticals Co., Ltd. faced a challenging trading day on October 14, 2025, with a notable stock decline. Despite recent downturns, the company has achieved a strong annual return and maintains a significant market capitalization, alongside a high price-to-earnings ratio and a modest dividend yield.

Betta Pharmaceuticals Hits Day Low of CNY 65.03 Amid Price Pressure

Betta Pharmaceuticals Co., Ltd. saw a significant decline in its stock today, contrasting with the broader market's performance. Despite recent losses, the company has demonstrated strong long-term growth, with notable increases in stock value over the past year and three years, alongside key financial metrics reflecting its industry standing.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

12.38%

EBIT Growth (5y)

4.42%

EBIT to Interest (avg)

9.58

Debt to EBITDA (avg)

1.94

Net Debt to Equity (avg)

0.31

Sales to Capital Employed (avg)

0.35

Tax Ratio

5.06%

Dividend Payout Ratio

20.68%

Pledged Shares

Institutional Holding

ROCE (avg)

5.85%

ROE (avg)

7.69%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.95

EV to EBIT

63.93

EV to EBITDA

31.49

EV to Capital Employed

3.99

EV to Sales

9.54

PEG Ratio

Dividend Yield

0.30%

ROCE (Latest)

6.24%

ROE (Latest)

6.92%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bearish

RSI

Bullish

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -11.11% vs 67.47% in Mar 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -63.14% vs 624.73% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "805.30",
          "val2": "906.00",
          "chgp": "-11.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "206.40",
          "val2": "344.00",
          "chgp": "-40.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "17.20",
          "val2": "21.60",
          "chgp": "-20.37%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.60",
          "val2": "-76.60",
          "chgp": "100.78%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "35.20",
          "val2": "95.50",
          "chgp": "-63.14%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "87.90%",
          "val2": "230.00%",
          "chgp": "-14.21%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 17.55% vs 3.52% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 16.01% vs 167.31% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,870.70",
          "val2": "2,442.10",
          "chgp": "17.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "848.00",
          "val2": "583.10",
          "chgp": "45.43%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "46.90",
          "val2": "56.50",
          "chgp": "-16.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-53.80",
          "val2": "-4.90",
          "chgp": "-997.96%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "387.00",
          "val2": "333.60",
          "chgp": "16.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "165.80%",
          "val2": "114.50%",
          "chgp": "5.13%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

805.30

906.00

-11.11%

Operating Profit (PBDIT) excl Other Income

206.40

344.00

-40.00%

Interest

17.20

21.60

-20.37%

Exceptional Items

0.60

-76.60

100.78%

Consolidate Net Profit

35.20

95.50

-63.14%

Operating Profit Margin (Excl OI)

87.90%

230.00%

-14.21%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -11.11% vs 67.47% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -63.14% vs 624.73% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

2,870.70

2,442.10

17.55%

Operating Profit (PBDIT) excl Other Income

848.00

583.10

45.43%

Interest

46.90

56.50

-16.99%

Exceptional Items

-53.80

-4.90

-997.96%

Consolidate Net Profit

387.00

333.60

16.01%

Operating Profit Margin (Excl OI)

165.80%

114.50%

5.13%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 17.55% vs 3.52% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 16.01% vs 167.31% in Dec 2023

All Annual Results

Company CV

About Betta Pharmaceuticals Co., Ltd.

Betta Pharmaceuticals Co., Ltd.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Betta Pharmaceuticals Co., Ltd.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

Poor long term growth as Net Sales has grown by an annual rate of 12.38% and Operating profit at 4.42% over the last 5 years

Negative results in Jun 25

With ROE of 6.92%, it has a very expensive valuation with a 4.95 Price to Book Value

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Betta Pharmaceuticals Hits Day Low of CNY 56.56 Amid Price Pressure

Betta Pharmaceuticals Hits Day Low of CNY 56.08 Amid Price Pressure

Betta Pharmaceuticals Hits Day Low of CNY 65.03 Amid Price Pressure

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Betta Pharmaceuticals Co., Ltd.

Company Coordinates